YourLawyer.com® 1-800-LAW-INFO (1-800-529-4636)


AddThis Social Bookmark Button

Injured by Lexapro?

On December 13, 2006, the FDA announced antidepressants prescribed to young adults are risky. The agency proposed expanding the labels of all antidepressants to include an expanded warning of suicidal thoughts in patients ranging from 18-24 years of age. The newly presented change would expand a warning now on the labels that pertain only to children and adolescents treated with antidepressant drugs. The new label changes would also contain a suggestion that patients of all ages be carefully monitored, particularly when starting antidepressant treatment.

The FDA recently completed a bulk evaluation of 372 studies involving approximately 100,000 patients and 11 antidepressants, including Lexapro, Zoloft, Prozac and Paxil. When the results are analyzed by age, it becomes clear there is an elevated risk for suicidal thoughts and behavior among adults 18 to 25 that approaches that seen in children, the FDA said in documents released before their scheduled December 13, 2006 meeting of its psychopharmacologic drugs advisory committee.

In May 2006, GlaxoSmithKline and the FDA cautioned Paxil may raise the risk of suicidal behavior in young adults too and changed the drug’s label to reflect that risk. In the United States, use of antidepressants for patients under 18 years has not been approved by FDA, with the exception of Prozac. This means that both the healthcare professional who prescribes or dispenses these drugs for children and adolescents and the pharmaceutical company that promotes this "off-label" (unapproved) use knowingly take a risk with the patient's safety.  Antidepressants are widely suspected of contributing to suicidal and/or violent behaviors, especially in children. This point of view has recently been adopted by the U.S. Food and Drug Administration (FDA), somewhat more slowly than its British counterpart, the Medicines Control Agency.

Newer anti-depressants such as Lexapro, known as selective serotonin reuptake inhibitors (SSRIs), have come under recent scrutiny. Lexapro is prescribed to treat major depression. In March, the Food and Drug Administration asked the makers of SSRIs to include warnings that children and adults might become more depressed or suicidal while taking these drugs, and that close supervision, particularly at the start of treatment, is required.

Forest Pharmaceutical, the manufacturer of Lexapro, continues to downplay the drug's dangers.

Lexapro side effects include: Insomnia, Diarrhea, Dry Mouth, Somnolence (sleepiness or drowsiness), Dizziness, Increased Sweating, Constipation, Fatigue, Indigestion, Ejaculation Disorder (male), Decreased Libido (decreased sex drive) (both male and female), Impotence (male), Influenza-Like Symptoms (flu-like symptoms), Appetite Decreased, Rhinitis (runny nose), Sinusitis (inflammation of the sinuses), Possible Impairment of Fertility (inability to get pregnant), Danger of Birth Defects (Pregnant Females), Passing of Drug to Nursing Babies, Danger to Patients With History of Mania, Danger to Patients with History of Seizures, Danger to Patients with Suicidal Tendencies (note: Drugs such as Lexapro have been present in numerous suicide cases, although drug companies have denied the drugs as causes). Additional side effects include: Interference with operation of machinery including automobiles, Impairment of Judgment, Priapism (males) (Persistent, usually painful erection of the penis, especially as a consequence of disease and not related to sexual arousal).

In addition to the aforementioned side effects associated with antidepressants, a new study has linked these drugs to an increased risk of death amongst patients with coronary artery disease. This study, which was conducted at Duke University, analyzed the survival rate of heart disease patients using antidepressants compared with those not using these drugs. 

During an average of three years of follow-up, 21.4% of the patients taking antidepressants died compared with 12.5% of those not on antidepressants. After adjusting for demographic factors, cardiac risk factors, scores on the Beck Depression Inventory test, and the presence of other illness, antidepressant use was an independent risk factor for mortality, increasing the risk by 62%.

Researchers do not fully understand why antidepressants increase the risk of mortality in these patients. However their findings are statistically significant and show that these drugs do increase the risk of death in heart disease patients. Current and former heart disease patients should weigh the risks and benefits of antidepressants before using these medications.

If you or a loved one took Lexapro and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney.
LexaproRSS Feed

SSRI Antidepressants May Up Stroke Risk After Menopause

Dec 17, 2009 | Parker Waichman Alonso LLP
Post-menopausal women taking selective serotonin reuptake inhibitor (SSRI) antidepressants have a small, though statistically higher risk of stroke, according to a newly published study.  SSRIs include the drugs Prozac, Paxil, Zoloft, Lexapro, and Celexa.Antidepressant use in the US has more than quintupled since the early 1990s, and SSRIs have  replaced older medications called tricyclic antidepressants, which can be toxic the heart.  According to a press release announcing this...

Another Study Links Antidepressants To Birth Defects

Sep 25, 2009 | Parker Waichman Alonso LLP
More emerging research is  pointing to links between antidepressant use and a greater chance for a particular heart birth defect, writes WebMD.A Danish study of over 400,00 children born from 1996 to 2003, found that the risk increased when expectant mothers either take more than one selective serotonin reuptake inhibitor (SSRI) or switch SSRIs in early trimesters, said WebMD.  Popular SSRIs include Prozac, Paxil, Zoloft, Celexa, and Lexapro, and are often prescribed to pregnant women...

JAMA Oversight Committee to Look Into Lexapro Study Controversy

Mar 30, 2009 | Parker Waichman Alonso LLP
The American Medical Association (AMA) is responding to allegations that two top editors of  the Journal of the American Medical Association  (JAMA) attempted to intimidate a critic of a Lexapro study it published.  According to The Wall Street Journal, the AMA has asked its oversight committee to investigate the charges.The controversy centers on Dr. Jonathan Leo's criticism of a Lexapro study published in the JAMA.  Dr. Leo is a professor of neuroanatomy at Lincoln...

JAMA Slammed Over Lexapro Study Debacle

Mar 27, 2009 | Parker Waichman Alonso LLP
A nonprofit group has criticized the Journal of the America Medical Association (JAMA) over its treatment of a researcher who questioned a Lexapro study it published. According to The Wall Street Journal, the Alliance for Human Research Protection is calling for the suspension of two JAMA editors because of their role in the debacle. The Alliance is a group that has long criticized the ties between the drug industry and academia, the Journal said.In a letter to the chairman of the JAMA board of...

Depression Med Linked to Pediatric Suicide Approved by FDA for Kids

Mar 24, 2009 | Parker Waichman Alonso LLP
Although it has long been known that antidepressants are dangerous for pediatric patients, Forest Laboratories just announced that its antidepressant Lexapro (escitalopram oxalate) has been approved for major depressive disorder (MDD) in children aged 12 to 17 reports HealthDay News.According to Forest Laboratories, about two million teenagers in this country have experienced MDD in the past year, said HealthDay News; a fact used to market Lexapro to young patients despite evidence showing...

More Lexapro News

Lexapro
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date you stopped taking the drug (mm-yyyy):

Date you started taking the drug (mm-yyyy):

Name(s) of all antidepressants taken:

Age of patient when antidepressant(s) prescribed:

What condition was this medication prescribed to treat?

Was suicide attempted after taking antidepressant(s)?


Did attempted suicide result in death?


Was hospitalization or institutionalization required after taking antidepressant(s)?


Please further describe side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Home | Defective Drugs | Medical Devices | Toxic Substances | Accidents | Product Liability | Malpractice | Diseases
Nursing Home Negligence | Food Poisoning | Other Topics | Contact
Statement of Clients' Rights | Site Map | Vioxx | Mesothelioma | Permax | Dostinex | Composix Kugel Mesh X Large Patch
Ortho Evra | Fosamax | Fusarium Keratitis | Stevens Johnson Syndrome

© 2002-2010 YourLawyer.com®. All Rights Reserved.

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Attorney Advertising